TELA Bio (TELA)
NASDAQ:TELA
TELA Stock Chart & Stats
$0.74
$0.04(1.41%)
At close: 4:00 PM EST
$0.74
$0.04(1.41%)
Day’s Range― - ―
52-Week Range$0.60 - $2.20
Previous CloseN/A
Volume34.27K
Average Volume (3M)90.44K
Market Cap
$29.98M
Enterprise Value$34.79M
Total Cash (Recent Filing)$50.84M
Total Debt (Recent Filing)$55.65M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 07, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding44,740,370
10 Day Avg. Volume68,447
30 Day Avg. Volume90,440
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)8.78
Price to Sales (P/S)0.69
P/FCF Ratio-1.93
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue0.43
Enterprise Value/Gross Profit0.64
Enterprise Value/Ebitda-1.09
Forecast
1Y Price Target
$2.00Price Target Upside170.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.57
Revenue Forecast (FY)$92.66M
Bulls Say, Bears Say
Bulls Say
Growth PotentialReaching the milestone of $100M in revenues brings the company closer to profitability and increases the tangibility of TELA as a take-out candidate.
LeadershipThe appointment of Jeff Blizard, who brings extensive leadership experience from Abiomed, is seen as a positive move for TELA's growth strategy.
Product SuccessNew products in both PRS and Hernia are anticipated to contribute to growth reacceleration.
Bears Say
Financial ChallengesDespite controlling some costs, the operating loss was higher than anticipated, suggesting financial challenges.
Funding NeedsThe company may need another round of financing to fund operations, which could negatively impact the stock.
Sales Force TurnoverThe departure of 11 of 69 high-performing territory managers led to a significant drop in sales.
TELA Bio News
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $0.60 and its highest was $2.20 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $29.98M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is May 07, 2026 which is in 38 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on Mar 24, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.178 by $0.008.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.19.
How many shares outstanding does TELA Bio have?
TELA Bio has 44,740,370 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.178. Following the earnings report the stock price went down -9.33%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call described meaningful operational and commercial progress—16% full-year revenue growth, strong unit gains, margin improvement, European traction, product launches, and a rebuilt sales organization—while candidly acknowledging near-term execution risks: a large cohort of new reps ramping, contract execution delays, product-mix pressure on ASPs, and a more conservative 2026 guide (at least 8%). The tone is constructive and forward-looking with prudence in guidance; fundamentals improved but short-term variability is expected as the commercial changes annualize.View all TELA earnings summariesTELA Stock 12 Month Forecast
Average Price Target
$2.00
▲(170.27% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
20.80% Insiders
5.22% Mutual Funds
51.09% Other Institutional Investors
19.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---